NVZMY (Novonesis (Novozymes) B) Earnings per Share (Diluted) : $1.05 (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Earnings per Share (Diluted)?

Novonesis (Novozymes) B's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $0.43. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $1.05.

Novonesis (Novozymes) B's EPS (Basic) for the three months ended in Mar. 2025 was $0.43. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $1.05.

Novonesis (Novozymes) B's EPS without NRI for the three months ended in Mar. 2025 was $0.45. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $1.26.

During the past 12 months, Novonesis (Novozymes) B's average EPS without NRIGrowth Rate was -32.00% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -12.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.90% per year.

During the past 13 years, Novonesis (Novozymes) B's highest 3-Year average EPS without NRI Growth Rate was 18.50% per year. The lowest was -12.40% per year. And the median was 10.80% per year.

Novonesis (Novozymes) B Earnings per Share (Diluted) Historical Data

The historical data trend for Novonesis (Novozymes) B's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Earnings per Share (Diluted) Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Earnings per Share (Diluted)

Get a 7-Day Free Trial

1.64

1.71

1.88

1.59

0.70

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Earnings per Share (Diluted)	Get a 7-Day Free Trial															0.86	0.09	0.07	0.56	0.43

Competitive Comparison of Novonesis (Novozymes) B's Earnings per Share (Diluted)

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novonesis (Novozymes) B's PE Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's PE Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's PE Ratio falls into.

Save Embed

;

Save Embed

;

Novonesis (Novozymes) B Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Novonesis (Novozymes) B's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(320.209	-	0)	/	459.605
	=	0.70

Novonesis (Novozymes) B's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(201.081	-	0)	/	468.100
	=	0.43

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Novonesis (Novozymes) B (OTCPK:NVZMY) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Novonesis (Novozymes) B Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMY) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

NVZMF:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.